Skip to search formSkip to main contentSkip to account menu

MLN-518

Known as: CT-53518, CT53518, MLN518 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD+ acute myeloid… 
Review
2010
Review
2010
  • P. Wiernik
  • Clinical advances in hematology & oncology : H&O
  • 2010
  • Corpus ID: 43049364
The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and… 
Highly Cited
2009
Highly Cited
2009
Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML… 
Highly Cited
2006
Highly Cited
2006
Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine… 
Highly Cited
2004
Highly Cited
2004
FLT3 is constitutively activated by internal tandem duplications (ITDs) in the juxtamembrane domain or by activation loop… 
Highly Cited
2004
Highly Cited
2004
Oncogenic mutations of the receptor tyrosine kinase KIT occur in gastrointestinal stromal tumors (GISTs), some cases of acute… 
2004
2004
Internal tandem duplications (ITDs) of the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase are found in approximately… 
2004
2004
MLN518 is a small molecule inhibitor of FLT3, PDGFR and c-Kit that is currently being evaluated as a therapy for AML. Previous… 
Highly Cited
2002
Highly Cited
2002
We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent…